Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trimlife acquired

This article was originally published in The Tan Sheet

Executive Summary

Neutraceutical Company says it acquired nutritional supplement company Trimlife to introduce wellness products and services on an "aggressive" timetable with a concentration on quality and safety. "Our expansion will focus on healthy, organic, natural aids to common issues affecting many of us," the Fort Lee, N.J.-based firm says Jan. 30. New initiatives include a seven-step wellness program. The firm recently introduced Lipitone Advanced, a weight-loss brand that contains fat-blocking and carb-loading herbal ingredients and increases energy levels, the firm claim

You may also be interested in...



Supplements’ Direct Response Marketing Success Sets Off FTC Alarm

Dietary supplement firms could face more aggressive enforcement from the Federal Trade Commission as they take advantage of increased direct response marketing opportunities created by the recession

Entries Begin To Roll In For 2024 Industry Awards

Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.

‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach

In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel